
Recipharm appoints Hans Lennernäs to operating Board
pharmafile | February 5, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Recipharm
Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company’s Board of directors.
Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery.
Lennernäs has served as the principal investigator in an extensive collaboration with the FDA, University of Michigan, US, and Medical Product Agency, Sweden over the course of several years in which he developed a new guideline for the Biopharmaceutics Classification System.
In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.
“I am very much looking forward to serving on the Board of directors at Recipharm Pharmaceutical Development AB,” Lennernäs commented.
“We are very pleased to welcome a Board member of Hans Lennernäs calibre,” remarked general manager Maria Lundberg.
“His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for Phase I, II and III clinical trials, makes him an excellent addition to the Board.”
Related Content

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

Recipharm designates Germany site as Centre of Excellence
The multi-product facility recently underwent significant renovations

Strategic alliance announced between Recipharm and Exela
Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The …






